CLRB

Cellectar Biosciences, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.86
52-Week Range: $1.78 – $6.52
Market Cap: $16.82M
P/E (TTM): —
EPS (TTM): -3.46
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.49
PEG Ratio: —
Return on Equity: -119.57%
Return on Assets: -58.44%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.66
Debt/Equity: 0.05
Total Debt: $1.53M
Free Cash Flow: $-12.52M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-15.64M

CLRB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.27M	$27.27M	$26.14M	$11.50M
Selling, General & Admin	$10.55M	$11.69M	$25.64M	$11.48M
Operating Expenses	$28.81M	$38.96M	$51.78M	$22.98M
Operating Income	-$28.81M	-$38.96M	-$51.78M	-$22.98M
EBITDA	-$28.67M	-$38.77M	-$51.49M	-$22.77M
Pretax Income	-$31.85M	-$42.83M	-$44.52M	-$21.79M
Income Tax	-$60.00K	-$60.00K	$66.00K	$0.00
Net Income	-$31.79M	-$42.77M	-$44.58M	-$21.79M
Diluted EPS	-121.50	-105.00	-41.89	-8.35
Diluted Shares	235188	407385	1.24M	2.61M

CLRB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.87M	$9.56M	$23.29M	$13.20M
Current Assets	$20.53M	$10.45M	$24.25M	$14.04M
Total Assets	$21.59M	$12.08M	$25.47M	$14.98M
Current Liabilities	$11.50M	$25.36M	$9.39M	$4.75M
Total Debt	$603.83K	$552.98K	$494.00K	$409.59K
Total Liabilities	$13.44M	$27.23M	$11.18M	$6.44M
Retained Earnings	-$159.99M	-$202.76M	-$247.34M	-$269.13M
Shareholders' Equity	$8.15M	-$15.16M	$14.29M	$8.54M
Working Capital	$9.03M	-$14.91M	$14.86M	$9.29M

CLRB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$25.22M	-$32.38M	-$47.58M	-$23.12M
Capital Expenditure	-$225.97K	-$864.04K	-$104.19K	-$5.88K
Free Cash Flow	-$25.45M	-$33.24M	-$47.69M	-$23.12M
Depreciation & Amortisation	$148.44K	$192.38K	$291.65K	$213.60K
Stock-Based Compensation	$1.45M	$2.41M	$4.27M	$2.26M
Investing Cash Flow	-$225.97K	-$864.04K	-$104.19K	-$5.88K
Financing Cash Flow	$9.61M	$22.94M	$61.41M	$13.03M
Net Change in Cash	-$15.84M	-$10.30M	$13.72M	-$10.09M

CLRB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.43M	$2.39M	$2.52M	$3.16M	$3.01M	$4.56M
Selling, General & Admin	$2.97M	$3.65M	$2.33M	$2.53M	$2.79M	$2.64M
Operating Expenses	$6.40M	$6.04M	$4.85M	$5.69M	$5.79M	$7.20M
Operating Income	-$6.40M	-$6.04M	-$4.85M	-$5.69M	-$5.79M	-$7.20M
EBITDA	-$6.34M	-$5.98M	-$4.80M	-$5.64M	-$5.79M	-$7.16M
Pretax Income	-$6.60M	-$5.45M	-$4.44M	-$5.30M	-$5.65M	-$6.93M
Net Income	-$6.60M	-$5.45M	-$4.44M	-$5.30M	-$5.65M	-$6.93M
Diluted EPS	-4.30	-3.39	-1.41	—	-1.33	-0.57
Diluted Shares	1.54M	1.61M	3.16M	—	4.24M	12.23M

CLRB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$13.91M	$11.04M	$12.55M	$13.20M	$8.35M	$33.99M
Current Assets	$14.89M	$12.62M	$13.62M	$14.04M	$9.27M	$34.88M
Total Assets	$16.04M	$13.70M	$14.63M	$14.98M	$11.12M	$36.64M
Current Liabilities	$6.02M	$5.87M	$4.91M	$4.75M	$4.87M	$5.24M
Total Debt	$474.35K	$453.51K	$431.93K	$409.59K	$1.53M	$1.53M
Total Liabilities	$7.79M	$7.61M	$6.63M	$6.44M	$7.78M	$6.77M
Retained Earnings	-$253.95M	-$259.39M	-$263.84M	-$269.13M	-$274.79M	-$281.72M
Shareholders' Equity	$8.25M	$6.09M	$8.00M	$8.54M	$3.34M	$29.87M
Working Capital	$8.87M	$6.75M	$8.71M	$9.29M	$4.39M	$29.64M

CLRB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$9.38M	-$5.12M	-$4.28M	-$4.34M	-$4.85M	-$6.01M
Capital Expenditure	—	—	—	—	-$3.38K	—
Free Cash Flow	-$9.38M	-$5.12M	-$4.28M	-$4.35M	-$4.85M	-$6.01M
Depreciation & Amortisation	$56.30K	$55.56K	$52.28K	$49.46K	-$110.02K	$35.52K
Stock-Based Compensation	$562.74K	$565.39K	$567.79K	$567.79K	$451.87K	$428.31K
Investing Cash Flow	$0.00	$0.00	$0.00	-$5.88K	-$3.38K	$0.00
Financing Cash Flow	$0.00	$2.25M	$5.79M	$4.99M	—	—
Net Change in Cash	-$9.38M	-$2.86M	$1.51M	$641.74K	-$4.85M	$25.65M

Market Snapshot

About

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer treatment. Headquartered in Florham Park, New Jersey, the company's proprietary phospholipid ether (PLE) platform selectively delivers radiation to cancer cells and the tumor microenvironment. Cellectar's lead product candidate, iopofosine I 131, is being evaluated for relapsed/refractory multiple myeloma and other hematologic malignancies. The PLE platform's tumor-targeting mechanism offers potential advantages over conventional radiotherapy by concentrating therapeutic radiation while sparing healthy tissue.